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 Abstract
Increasing evidence has shown that diabetes may be associ­
ated with learning and memory deficits in humans. These 
cognitive disorders, called ‘diabetic encephalopathy’, can 
impair the daily performance of diabetic individuals. In re­
cent years, some neuroprotective measures have been pro­
posed to prevent diabetic neuropathology. This review at­
tempts to show a summary of different experimental mea­
sures that have been described to improve the burden of 
diabetes in the central nervous system, particularly hippo­
campal formation. Copyright © 2010 S. Karger AG, Basel 
 Introductory Remarks
Increasing evidences have shown that diabetes may be 
associated with learning and memory deficits in humans
[1–3]. It seems that diabetes is associated with gradually 
developing end-organ damage in the central nervous 
system. This relatively unknown complication can be 
referred to as ‘diabetic encephalopathy’ and is charac­
terized by electrophysiological and neuroradiological 
changes, such as delayed latencies of evoked potentials, 
modest cerebral atrophy and (periventricular) white mat­
ter lesions  [4]. The emerging view is that the diabetic
brain features many symptoms that are best described as
‘accelerated brain ageing’  [5]. Sima et al. [6] suggested two 
types of diabetic encephalopathy. Primary diabetic en­
cephalopathy which is caused by hyperglycemia and im­
paired insulin action particularly in type 1 diabetes.
Apoptotic neuronal loss and cognitive decline is associ­
ated with this type in a duration-related fashion. Second­
ary diabetic encephalopathy seems to arise from hypoxic­
ischemic insults due to underlying microvascular disease 
or as a consequence of hypoglycemia  [6] .
The mechanism(s) by which cognitive abilities are im­
paired in diabetes has/have not been identified clearly [7] . 
Recent evidence has shown that the process of neurogen­
esis, which includes cell proliferation, survival, migration 
and differentiation, continues in the hippocampal forma­
tion well into adulthood in a variety of species, including 
rodents, nonhuman primates as well as humans [7–11] . 
Increasing data suggest a diminished neurogenesis as the 
culprit for diabetic encephalopathy [7, 12, 13]. In conjunc­
tion, it is now well understood that the oxidative injury
underlies the neuronal injury in the central nervous sys­
tem following diabetes [14–16].
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Experimental Neuroprotective Measures in Diabetic 
Encephalopathy
During the last few years, different strategies to pre­
vent and treat diabetic encephalopathy have been consid­
ered. Given the underlying mechanisms for diabetic en­
cephalopathy, the neuroprotective measures have focused 
mainly on the reduction of oxidative stress and the 
prevention of apoptosis to avoid neuronal loss. In what
follows, some of the different experimental measures 
for neuroprotection in diabetic encephalopathy are de­
scribed.
 Antioxidant Agents 
Ates et al.  [14] investigated the possible neuroprotec­
tive effect of resveratrol against streptozotocin (STZ)-in­
duced hyperglycemia in the rat brain and medulla spina­
lis. They showed that daily intraperiteonal injection of
resveratrol (10 mg/kg) to STZ-induced diabetic rats over 
6 weeks can significantly reduce malondialdehyde, xan­
thine oxidase, and nitric oxide production and increase
glutathione levels. Also, Ates et al.  [15] demonstrated a
significant elevation of malondialdehyde, xanthine oxi­
dase and nitrite levels in the hippocampus, cortex, cere­
bellum, brain stem and spinal cord of the diabetic rats
while a 6-week treatment with etomidate (2 mg/kg/day)
provided significantly lower values. Furthermore, they
suggested that mexiletine (50 mg/kg/day for 6 weeks) can 
protect neuronal tissue against diabetic oxidative dam­
age  [16] .
 Kuhad and Chopra [17] investigated the effects of ses­
amol (3,4-methylenedioxyphenol), a phenolic antioxi­
dant and anti-inflammatory molecule, on cognitive func­
tions, oxidative stress and inflammation in diabetic rats.
Their findings showed that chronic treatment with sesa­
mol (2, 4 and 8 mg/kg; p.o.) significantly and dose-de­
pendently attenuated cognitive deficit, and reduced ace­
tylcholinesterase, oxidative stress and inflammation in
diabetic rats. They also demonstrated that chronic treat­
ment with curcumin (60 mg/kg; p.o.), a well-established 
phenolic antioxidant and anti-inflammatory molecule,
significantly attenuated cognitive deficit, cholinergic
dysfunction, oxidative stress and inflammation in dia­
betic rats [18]. Tuzcu and Baydas [19] showed that treat­
ment with melatonin and vitamin E significantly amelio­
rated learning and memory performance. Furthermore,
both antioxidants reversed lipid peroxidation and gluta­
thione levels toward their control values. 
Muriach et al.  [20] treated alloxan-injected diabetic
rats with lutein for 10 days. They reported no increase in
malondialdehyde and glutathione concentrations and 
glutathione peroxidase activity in the retina and hippo-
campus of lutein-treated rats. Diabetic rats received N­
acetylcysteine (1.4–1.5 g/kg body weight) for 8 weeks and 
demonstrated significantly improved lipid composition, 
restored membrane fluidity and activity of membrane-
bound enzymes. The authors proposed that N-acetylcys­
teine administration ameliorated oxidative stress and al­
terations in lipid composition induced by hyperglycemia 
[21] .
 Endocrine Hormones
Saravia et al.  [22] found that diminished neurogenesis
in the dentate gyrus of STZ-induced diabetic adult mice
was completely relieved by 10 days after estradiol pellet
implantation. In addition, the increased markers of astro­
gliosis and ongoing neuronal dysfunction were reverted 
to normal by the estradiol regime that upregulated cell
proliferation. They also previously showed that 17[ -es­
tradiol (200 µg pellet implant in cholesterol during 10
days) can restore dentate gyrus cell proliferation in the 
diabetic mouse brain  [23] .
In addition to gene-regulatory effects of insulin and 
C-peptide on axonal cytoskeletal proteins and nerve fiber 
integrity, which are favorable in diabetic polyneuropathy,
C-peptide is proposed to have some beneficial effects on
primary diabetic encephalopathy [24]. It has been shown 
that C-peptide replacement partially prevents hippocam­
pal neuronal apoptosis and cognitive deficits [25] . Sima 
et al.  [26] showed that full insulinomimetic C-peptide  
replacement can significantly prevent upregulation of
RAGE and NF-KB in diabetic rat hippocampus. The 
treatment can be associated with lower expression of
TNF-a , IL-1[, IL-2 and IL-6 in hippocampi of diabetic
rats and is likely to improve the oxidative and apoptotic 
neuronal cell death  [26] .
 Medications 
Some heterogenic medications with neuroprotective 
property have been suggested during recent years. For  
example, Beauquis et al. [27] examined the neuroprotec­
tive efficacy of a selective serotonin reuptake inhibitor,
fluoxetine (10 mg/kg/day, i.p., 10 days) in diabetic C57BL/6 
mice. They demonstrated that fluoxetine preferentially
increased the proliferation of cells with a neuronal phe­
notype and prevented hilar cell loss within the dentate 
gyrus  [27] .
 Tsukuda et al. [28] showed that oral administration of
nifedipine, a calcium channel blocker, at a nonhypoten­
sive dose (0.001% in laboratory chow) to KK-A(y) type 2 
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diabetic mice from 10 weeks of age improved cognitive 
function. Nifedipine treatment decreased the serum in­
sulin level to one fifth of that in KK-A(y) diabetic mice. 
Moreover, nifedipine treatment significantly reduced su­
peroxide anion production in the brain. Furthermore, 
treatment with nifedipine markedly reduced the mRNA
level of Id-1, an inhibitor of neural differentiation, in the 
hippocampus. Therefore, Tsukuda et al.  [28] concluded 
that nifedipine ameliorates impaired cognitive function
in type 2 diabetic mice, because of attenuation of hyper­
insulinemia and superoxide production in the brain and 
possible upregulation of the neural differentiation-con­
trolling gene, Id-1. Moreover, Tsukuda et al.  [29] reported
improved cognitive function in KK-A(y) mice by oral ad­
ministration of candesartan at a nonhypotensive dose
(0.005% in laboratory chow). They suggested that cande­
sartan ameliorates the impaired cognitive function in
type 2 diabetes mice, because of an increased expression
of methyl methanesulfonate sensitive 2, a neuroprotec­
tive factor, in addition to improvement of glucose intoler­
ance [29] .
 Acupuncture 
Jang et al.  [30] showed that acupuncture at the Zusan­
li acupoint significantly increased expression of nitric ox­
ide synthase (NOS) under diabetic conditions and pro­
posed that acupuncture treatment may modulate NOS 
activity in the hippocampus under diabetic conditions. 
Moreover, it has been documented that acupuncture  
modulates NOS and neuronal NOS expressions in the ce­
rebral cortex of diabetic rats [31] .
 Exercise 
It has been shown that running on a treadmill (30 min 
each day) for 8 days is effective in enhancing hippocam­
pal granular cell proliferation in rats with STZ-induced 
diabetes [32]. In addition, Lee et al.  [33] showed a mark­
edly enhanced cell proliferation in the dentate gyrus of
hyperglycemic rats which had run on a treadmill for 30
min daily for 10 days. It has also been reported that pre­
synaptic impairment of synaptic plasticity in the dentate
gyrus under diabetic conditions may be prevented by
treadmill running (17 m/min for 40 min/day, 7 days/ 
week, for 12 weeks) [34] .
 Radiation 
After 0.01 Gy, 0.1 Gy, 1 Gy and 10 Gy radiation was 
delivered, Kang et al. [35] showed an increase in dentate
gyrus proliferating cells and suggested that low doses of
radiation (i.e. 0.01 and 0.1 Gy) paradoxically improved 
diabetes and induced neuronal cell suppression in the 
hippocampal dentate gyrus of rats.
 Plant Materials 
The use of plant materials is increasing in all fields of
medicine. Recently, some plant extracts of different geo­
graphical origins have been shown to protect the central 
nervous system against insults of diabetes.
 Lim et al. [36] studied the effect of an aqueous extract 
of Ginseng radix on cell proliferation in the dentate gyrus
of 7-week-old STZ-induced diabetic rats. They adminis­
tered the extract at different doses (10, 50, 100, and 200 
mg/kg) as well as for different durations (5 and 10 days) 
under both diabetic and control conditions. Ginseng ra­
dix had no significant effect on cell proliferation under 
normal conditions, while it enhanced new cell formation 
significantly under diabetic conditions. However, the 
proliferating effect of Ginseng radix was observed only at
a dose of 50 mg/kg. In addition, there was no significant 
difference in the number of proliferating cells between 5 
and 10 days of treatment. They attributed the observed 
neuroprotective effects of Ginseng radix to saponins
which are key pharmacological components of the ex­
tract. Previous studies have reported that some groups of
saponins increase the release of acetylcholine and the 
number of choline uptake sites in the rat hippocampus 
and also increase the expression of choline acetyltrans­
ferase in the basal forebrain. The authors concluded that
it is possible that ginseng saponin exerts its memory-en­
hancing effects via upregulating the cholinergic system 
[36]. Furthermore, Chang et al.  [37] showed that admin­
istration of Ginseng radix suppressed enhanced NOS ex­
pression in the hippocampus of diabetic rats and suggest­
ed that Ginseng radix may aid the treatment of central 
nervous system complications in diabetes. Jang et al.  [38]
reported that administration of ginseng radix enhanced 
the STZ-induced inhibition of c-Fos expression both
dose- and duration-dependently and may alleviate this
diabetes-induced disturbance in hippocampal func­
tions. 
Kim et al.  [39] showed that cell proliferation in the
dentate gyrus was suppressed in rats with STZ-induced 
diabetes, and treatment with Folium mori was shown to
increase new cell formation in the dentate gyrus in both
normal rats and those with STZ-induced diabetes. In ad­
dition, treatment with F. mori in normal rats and those 
with STZ-induced diabetes was shown to enhance neu­
ropeptide Y expression in the dentate gyrus. It has been 
concluded that the increase in the expression of neuro­
peptide Y in the dentate gyrus induced by the treatment 
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with F. mori may be associated with the observed effect
of F. mori extract on cell proliferation. The authors sug­
gested that F. mori treatment may aid in the recovery
from the central nervous system complications of diabe­
tes mellitus by enhancing cell proliferation in the dentate 
gyrus via augmented neuropeptide Y expression. 
Shin et al. [40] reported that treatment with 50–200
µg/kg/day of the aqueous extract of Rhizoma anemar­
rhenae for 7 days increased new cell formation and neu­
ropeptide Y expression in the dentate gyrus of diabetic
rats which was reduced by treatment with STZ in rats. 
Fazeli et al.  [41] showed that the administration of the
hydroalcoholic extract of nettle (Urtica dioica, 100 mg/ 
kg/day) for 4 weeks stopped diabetes-induced granule 
cell loss within the dentate gyrus of STZ-induced dia­
betic rats. They suggested that the nettle extract can ame­
liorate cognitive dysfunction seen in diabetes. Gülçin et
al.  [42] described some antioxidant properties of nettle
extract including inhibition of fatty acid peroxidation, 
effective reduction of power, free radical scavenging, 
superoxide anion radical scavenging, hydrogen peroxide 
scavenging, and metal chelating activities. In addition, 
the level of free electron accumulation in several rat brain 
areas such as the right frontal lobe has been decreased 
following nettle leaf supplementation [43, 44] . In con­
junction with antioxidant activity, it was documented 
that the nettle extract may have anti-apoptotic and cell
survival-supporting effects  [44] .
Aucubin is an iridoid glycoside that is commonly 
found in plants. Xue et al.  [45] proposed that administra­
tion of aucubin (5 mg/kg; i.p.) in diabetic rats can im­
prove unfavorable changes in pyramidal cell ultrastruc­
ture, proportions of apoptotic cells and survivability of
neuronal cells by modulating the expressions of Bcl-2 and 
Bax genes. In addition, it has been documented that au­
cubin at doses of 0, 1, 5 or 10 mg/kg can show some neu­
roprotective properties probably through promotion of
endogenous antioxidant enzymatic activities [46] .
New Prospective for Future Researches
Some new strategies, agents and interventions are un­
der study in other fields which may have some potential 
neuroprotective property in diabetic encephalopathy. For
example, exogenous erythropoietin showed some poten­
tial for neuroprotection in brain ischemia or trauma. It
has been found that exogenous erythropoietin infusion
can improve the ischemic damage of hippocampal CA1 
neurons and ischemia-induced learning deficits. Fur­
thermore, enhanced cognitive functioning in a condi­
tioned taste aversion mouse model has been reported fol-
lowing intraperitoneal exogenous erythropoietin admin­
istration [47]. Now, it is demonstrated that reductions of
brain temperature may be associated with robust neuro­
protection for hypoxia-ischemia in the brain of labora­
tory animals. In addition, Laptook  [48] proposed some
therapeutic benefits of hypothermia for term infants with
hypoxic-ischemic encephalopathy. It is supposed that hy­
pothermia may modify multiple cascades of events that
contribute to brain injury. The finding may be beneficial
for cognitive deficits seen in diabetic individuals. Inflam­
matory cascades and mediators including transcription 
factors are considered to contribute to the postischemic
neuroinflammation. The binding agonists of PPAR iso­
forms (a transcription factor) showed some neuropro­
tection in ischemic brain probably through preventing 
inflammatory gene expression, inducing antioxidant en­
zymes and other neuroprotective transcripts. Conse­
quently, PPAR-) agonists and similar agents can be de­
veloped as future therapeutics for ischemic as well as dia­
betic encephalopathy [49] .
Ischemic preconditioning has been associated with
some neuroprotective benefits. It was shown that isch­
emic preconditioning can inhibit the cytosolic release of
cytochrome C and reduce the activation of caspase-9 ac­
tivation. These mitochondrial changes following isch­
emic preconditioning can mediate the potential neuron-
preserving property against apoptosis  [50] .
 Concluding Remarks
Neuroprotection in diabetic encephalopathy is a new­
ly opened up venue in medical research. The reversibility 
of hippocamapal neuropathology through the modula­
tion of the neurogenesis within the dentate gyrus might 
give hope for different potential measures which can up-
regulate cell proliferation and compensate the neuronal
loss. Furthermore, a variety of new antioxidants/anti­
apoptotic agents and interventions as neuroprotective 
agents can be found against the underlying oxidative in­
jury as well as neuronal apoptosis.
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